PIM
EIDX

Partner Investment Management’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Partner Investment Management’s Portfolio EIDX Stock Details EIDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-607
Closed -$22K – 75
2019
Q3 		$22K Buy
+607
New +$23.7K 0.04% 67

Other funds holding EIDX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return

Partner Investment Management's EIDX Position: Q4 2019 in Review

Partner Investment Management sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q4 2019, closing a stake of 607 shares — an estimated $22K sold.

Partner Investment Management first reported a position in EIDX in Q3 2019 and held it in 1 quarter. The position peaked at $22K in Q3 2019. 102 funds tracked by Wall St. Rank hold EIDX as of Q4 2019.

  • Partner Investment Management reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • Partner Investment Management sold 607 Eidos Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $22K.
  • Partner Investment Management first reported a position in Eidos Therapeutics, Inc. Common Stock in Q3 2019 and held it in 1 quarter.
  • Partner Investment Management's Eidos Therapeutics, Inc. Common Stock position peaked at $22K in Q3 2019.
  • 102 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q4 2019.

Based on Partner Investment Management's 13F filing for Q4 2019, filed 14 Feb 2020.